# Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C

> **NCT03416491** · PHASE2 · COMPLETED · sponsor: **Kawin Technology Share-holding Co., Ltd.** · enrollment: 110 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** KW-136
- **DRUG:** Sofosbuvir

## Key facts

- **NCT ID:** NCT03416491
- **Lead sponsor:** Kawin Technology Share-holding Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-15
- **Primary completion:** 2017-09-17
- **Final completion:** 2017-11-08
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2018-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03416491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03416491, "Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03416491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*